Prelude Therapeutics Stock Forecast, Price & News

-0.31 (-0.97 %)
(As of 08/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume307,253 shs
Average Volume220,391 shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PRLD News and Ratings via Email

Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Prelude Therapeutics logo

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.


Prelude Therapeutics (NASDAQ:PRLD)  Shares Down 4.2%
Prelude Therapeutics (NASDAQ:PRLD) Shares Down 4.2%
July 28, 2021 |
Why BofA Is Turning Bullish On Prelude Therapeutics
Why BofA Is Turning Bullish On Prelude Therapeutics
July 27, 2021 |
Prelude Therapeutics (NASDAQ:PRLD) Shares Gap Up to $33.33
Prelude Therapeutics (NASDAQ:PRLD) Shares Gap Up to $33.33
July 27, 2021 |
Prelude Therapeutics (NASDAQ:PRLD) Upgraded at Bank of America
Prelude Therapeutics (NASDAQ:PRLD) Upgraded at Bank of America
July 27, 2021 |
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 4.8%
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 4.8%
July 23, 2021 |
Prelude Therapeutics (NASDAQ:PRLD)  Shares Down 5.2%
Prelude Therapeutics (NASDAQ:PRLD) Shares Down 5.2%
July 21, 2021 |
Prelude Therapeutics (NASDAQ:PRLD) Shares Gap Down to $31.37
Prelude Therapeutics (NASDAQ:PRLD) Shares Gap Down to $31.37
July 20, 2021 |
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 4.4%
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 4.4%
July 15, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.37 out of 5 stars

Medical Sector

178th out of 2,226 stocks

Pharmaceutical Preparations Industry

87th out of 870 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Prelude Therapeutics (NASDAQ:PRLD) Frequently Asked Questions

Is Prelude Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Prelude Therapeutics stock.
View analyst ratings for Prelude Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Prelude Therapeutics?

Wall Street analysts have given Prelude Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Prelude Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Prelude Therapeutics?

Prelude Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 3,400,000 shares, an increase of 32.3% from the June 15th total of 2,570,000 shares. Based on an average daily volume of 211,100 shares, the short-interest ratio is presently 16.1 days. Approximately 7.9% of the company's stock are sold short.
View Prelude Therapeutics' Short Interest

When is Prelude Therapeutics' next earnings date?

Prelude Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Prelude Therapeutics

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) posted its quarterly earnings results on Tuesday, May, 11th. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.05.
View Prelude Therapeutics' earnings history

What price target have analysts set for PRLD?

5 equities research analysts have issued 12 month price objectives for Prelude Therapeutics' stock. Their forecasts range from $37.00 to $80.00. On average, they anticipate Prelude Therapeutics' share price to reach $59.80 in the next year. This suggests a possible upside of 88.5% from the stock's current price.
View analysts' price targets for Prelude Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Prelude Therapeutics' key executives?

Prelude Therapeutics' management team includes the following people:
  • Dr. Krishna Vaddi D.V.M., Ph.D., Founder, CEO & Director (Age 55, Pay $645.73k)
  • Mr. Christopher Pierce M.B.A., Exec. VP & Chief of Bus. Operations (Age 41, Pay $336.37k)
  • Dr. Deborah Morosini, Exec. VP & Chief of Clinical Affairs (Age 62, Pay $326.81k)
  • Mr. Brian D. Piper M.B.A., MBA, Chief Financial Officer (Age 49)
  • Dr. Peggy A. Scherle Ph.D., Chief Scientific Officer (Age 60)
  • Dr. David J. Mauro, Chief Medical Officer (Age 56)
  • Dr. Andrew P. Combs Ph.D., Exec. VP & Head of Chemistry (Age 55)

Who are some of Prelude Therapeutics' key competitors?

When did Prelude Therapeutics IPO?

(PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

What is Prelude Therapeutics' stock symbol?

Prelude Therapeutics trades on the NASDAQ under the ticker symbol "PRLD."

Who are Prelude Therapeutics' major shareholders?

Prelude Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (0.04%). Company insiders that own Prelude Therapeutics stock include Brian Piper, Christopher Pierce, David J Mauro and Peggy Scherle.
View institutional ownership trends for Prelude Therapeutics

Which major investors are buying Prelude Therapeutics stock?

PRLD stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P..
View insider buying and selling activity for Prelude Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prelude Therapeutics' stock price today?

One share of PRLD stock can currently be purchased for approximately $31.73.

How much money does Prelude Therapeutics make?

Prelude Therapeutics has a market capitalization of $1.49 billion. The company earns $-56,930,000.00 in net income (profit) each year or ($4.56) on an earnings per share basis.

How many employees does Prelude Therapeutics have?

Prelude Therapeutics employs 105 workers across the globe.

What is Prelude Therapeutics' official website?

The official website for Prelude Therapeutics is

How can I contact Prelude Therapeutics?

The company can be reached via phone at 302-644-5427 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.